RAVULIZUMAB
ravulizumab 1.1 g/11 mL injection, 11 mL vial
RAVULIZUMAB (15225H)
15225H
Manner of administration:Injection
Restriction
Indication: Bridging therapy for generalised myasthenia gravis (gMG)
Treatment phase: Non-loading/maintenance doses
Restriction
Indication: Treatment refractory generalised myasthenia gravis (gMG)
Treatment phase: Initial treatment - Treatment refractory gMG patients (Non-loading/maintenance doses)
Restriction
Indication: Treatment refractory generalised myasthenia gravis (gMG)
Treatment phase: Continuing treatment - Treatment refractory gMG patients
Restriction
Indication: Treatment refractory generalised myasthenia gravis (gMG)
Treatment phase: Transitioning from non-PBS to PBS-subsidised treatment - Grandfathering treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 2 | DPMQ: $24,105.11 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Ultomiris | |||||